The Weight of It

How GLP-1 Actually Works

The hormone your gut releases when you eat, and why hijacking it with a weekly injection does something insulin never could.

Glucagon-like peptide-1 is an incretin — a hormone secreted by L-cells in the intestinal wall within minutes of eating. Its job is to trigger insulin release from the pancreas in direct proportion to how much glucose is present in the blood. That last detail is critical: GLP-1 only stimulates insulin when blood sugar is actually elevated, which is why these drugs essentially cannot cause hypoglycemia the way older diabetes medications do. The more glucose in the blood, the more GLP-1 fires the pancreas. When blood sugar normalizes, the signal stops.

But GLP-1 does considerably more than prod the pancreas. It suppresses glucagon (the hormone that tells the liver to dump sugar into the blood), slows gastric emptying (food sits in your stomach longer, so you feel full sooner and the glucose hit after eating is blunted), and — most importantly for the weight-loss story — acts directly on receptors in the hypothalamus to suppress appetite. You don’t just eat less because you’re full. You feel less of the drive to eat in the first place. The “food noise” — the background hum of thinking about food that many overweight patients report as near-constant — turns down or switches off entirely for many users. This is a central nervous system effect, not a stomach effect, and it’s why these drugs hit differently from every previous obesity treatment.

The problem with natural GLP-1 is its half-life: roughly two minutes. The enzyme DPP-4 shreds it almost as fast as the gut secretes it. Building a pharmaceutical-grade version means engineering a molecule that mimics GLP-1 but resists DPP-4 long enough to matter — which is the 120-year-old problem that pharmaceutical chemists only recently solved.

From Gila Monster Venom to Ozempic

A 120-year timeline from the concept of gut hormones to the most profitable drug class in history.

1902–1987The incretin concept and the gene

In 1902, British physiologists William Bayliss and Ernest Starling introduced the concept of secretin — a chemical signal from the gut that triggers the pancreas. French physiologist Jean La Barre coined the word “incretin” in 1932. It took fifty more years to find the actual molecule. In 1982–1983, Joel Habener, Svetlana Mojsov, and Daniel Drucker at Massachusetts General Hospital cloned the mammalian preproglucagon gene and discovered it encoded GLP-1 and GLP-2 alongside glucagon itself. In 1987, Mojsov and Habener identified the active truncated form. Danish researcher Jens Juul Holst independently demonstrated the same year that GLP-1 stimulates insulin secretion in humans in a glucose-dependent manner. The target was confirmed. Now the chemistry problem: how do you make a molecule that lasts long enough to be useful?

1992–2005Gila monster venom and the first drug

The answer came from a lizard. In 1992, endocrinologist John Eng at the Bronx VA Medical Center isolated exendin-4 from the saliva of the Gila monster. By accident of reptile evolution, exendin-4 shares 53% sequence homology with human GLP-1 but resists DPP-4 degradation almost entirely. It lasts long enough to do the job. Synthetic exendin-4 became exenatide (Byetta), approved by the FDA on April 28, 2005 — the first GLP-1 receptor agonist ever authorized. Twice-daily injection. Modest weight loss. Proof of concept delivered.

2010–2017Liraglutide and the first weight indication

Novo Nordisk’s liraglutide (Victoza) reached the FDA in January 2010. The chemistry improvement: a C16 fatty acid chain attached to the GLP-1 backbone via a glutamic acid spacer, allowing it to bind to albumin in the bloodstream and evade DPP-4. Half-life of 13 hours; once-daily injection. In December 2014, a higher dose of liraglutide was approved under the brand name Saxenda specifically for weight management — the first GLP-1 drug authorized for obesity rather than diabetes. The SCALE trials showed a mean 8% weight reduction over 56 weeks. That number would be dwarfed by what came next.

2017–2021Semaglutide: once a week, and the market explodes

Semaglutide represented a step-change in engineering. Novo Nordisk replaced a single amino acid (alanine at position 8, swapped for alpha-aminoisobutyric acid) to resist DPP-4 completely, then attached a C18 fatty diacid chain via a hydrophilic linker. Albumin binding extended the half-life to 165 hours — once-weekly injection. Ozempic was approved in December 2017 for type 2 diabetes. The SUSTAIN trials showed HbA1c reductions of up to 1.8% and cardiovascular safety. The FDA approved an oral version, Rybelsus, in 2019 using a novel absorption enhancer (SNAC) to survive the stomach.

Then came Wegovy. In June 2021, the FDA approved semaglutide at a higher dose (2.4 mg weekly) specifically for chronic weight management. The STEP 1 trial data: 1,961 participants, mean body weight reduction of 14.9% at 68 weeks versus 2.4% for placebo. The internet noticed. Ozempic prescriptions surged for off-label weight loss. Novo Nordisk could not manufacture enough. A shortage of a type 2 diabetes drug developed because wealthy people wanted to lose 30 pounds before their reunion.

2022–2023Tirzepatide: the dual agonist that beat everything

Eli Lilly answered Novo Nordisk with a dual agonist. Tirzepatide activates both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide — the other major incretin). The combination proved more powerful than either alone. Mounjaro was approved for type 2 diabetes in May 2022. In the SURPASS-2 head-to-head trial against semaglutide 1.0 mg, tirzepatide 15 mg achieved mean weight loss of 12.4 kg versus 6.2 kg for semaglutide — double the competition. Zepbound was approved for weight management in November 2023. The SURMOUNT-1 trial: 2,539 adults, tirzepatide 15 mg achieved a mean weight loss of 20.9% (23.6 kg) at 72 weeks versus 3.1% for placebo. Twenty percent. That number changed the conversation entirely.

Each generation more powerful than the last. Each requiring indefinite use to maintain results. Each priced to maximize lifetime revenue from a condition that never goes away on its own. The business logic is not subtle.

The Muscle Problem

When the scale goes down, roughly a quarter of what it measures is lean tissue. What that means for the other forty years of your life.

Every weight-loss intervention that works — caloric restriction, bariatric surgery, GLP-1 drugs — produces a mix of fat loss and lean mass loss. The question is the ratio. For GLP-1 monotherapy, the consistently reported figure is that 25 to 40% of total weight lost is lean mass, not fat. In practical terms: a patient who loses 50 pounds on Wegovy will lose somewhere between 12 and 20 pounds of that from muscle, bone mineral, water stored in muscle tissue, and organ mass.

The March 2026 BELIEVE trial (lead researcher Dr. Steven Heymsfield, Pennington Biomedical Research Center) provided the most precise data to date. In the semaglutide-alone arm, 24% of total weight lost was lean mass. In the combination arm (semaglutide plus bimagrumab, an activin receptor antagonist designed to preserve muscle), that figure fell to 8%. The comparison makes the default ratio starkly visible: one in four pounds lost on semaglutide alone is muscle you built over your lifetime.

The older you are, the worse this gets

A July 2025 retrospective cohort study (Ren, Zhi, Liu) followed 220 elderly patients (65+) with type 2 diabetes on semaglutide over 24 months. Grip strength — one of the most reliable predictors of long-term mortality and functional independence in the elderly — initially improved but then declined in male patients and continuously declined in female patients throughout the study. Gait speed, the other standard functional metric, decreased significantly in both sexes. Higher semaglutide dosage, low baseline muscle mass, and low baseline gait speed were all independent predictors of accelerated muscle wasting.

For older adults already on the edge of sarcopenia (pathologically low muscle mass), the weight that GLP-1 drugs successfully strip away may include muscle they cannot afford to lose. A University of Liverpool commentary published in the British Journal of Pharmacology in January 2026 made the point explicitly: measuring muscle mass on a DXA scan is the wrong metric. What matters is functional performance — can this person get up from a chair, walk without falling, carry groceries? Those outcomes are not systematically tracked in most GLP-1 clinical programs, because the trials were designed to measure weight, HbA1c, and cardiovascular events. Not whether someone’s grandmother can still climb stairs at 75.

Mitigation is real, but requires work

The lean mass loss is not inevitable. The research consistently shows that resistance training two to three times per week, combined with adequate dietary protein (at minimum 1.2 grams per kilogram of body weight daily, ideally 1.6 g/kg), substantially preserves muscle mass during GLP-1 therapy. The SEMALEAN study found that lean mass loss stabilized and stopped after month seven in patients who maintained adequate protein intake — even as weight continued to fall. The problem is that patients on GLP-1 drugs typically eat significantly less and often eat less protein, because GLP-1 suppresses appetite indiscriminately. You are less hungry for chicken breast and less hungry for french fries in equal measure. Getting to adequate protein on a dramatically reduced appetite requires deliberate effort that most patients — and most prescribing physicians — are not specifically counseled about.

The Gastrointestinal Reckoning

The most common reason people stop. Nausea, vomiting, constipation, and — in serious cases — a paralyzed stomach and a blocked bowel.

GLP-1 drugs slow gastric emptying. Food moves through your stomach more slowly. This is by design — it is part of how the drugs create satiety and blunt post-meal glucose spikes. The consequence, especially during dose escalation, is a gastrointestinal tract that does not want to cooperate. In the STEP trials, approximately 75% of semaglutide users reported at least one adverse event, compared to roughly 60% on placebo. The breakdown:

Most of these symptoms peak during the first weeks of each dose increase and then diminish as the body adapts. The standard clinical advice is to titrate slowly, eat smaller meals, avoid high-fat foods, and wait it out. For a significant share of patients, the nausea never fully resolves. Real-world data shows approximately 50% of patients discontinue semaglutide within one year, and 70 to 75% discontinue by year two. The primary driver of discontinuation is GI side effects, followed by cost.

Gastroparesis and the paralyzed stomach

At the far end of the GI risk spectrum is gastroparesis — stomach paralysis, where the stomach muscle stops contracting effectively and food simply sits there, undigested, sometimes for days. The FDA updated the prescribing information for Ozempic and Wegovy to include ileus (intestinal obstruction) in the postmarketing adverse reactions section after a pattern of hospitalizations emerged in the FDA Adverse Event Reporting System (FAERS). Cases of severe, persistent constipation progressing to fecal impaction and bowel obstruction have been reported. Rare fatalities are in the FAERS database.

The gastroparesis signal created a separate problem: anesthesia. If a patient’s stomach is not emptying normally and they go under general anesthesia, they may aspirate stomach contents into their lungs — a potentially fatal complication. In 2023, the American Society of Anesthesiologists (ASA) issued guidance recommending that patients stop weekly GLP-1 drugs one week before elective surgery to reduce the risk. The recommendation was quietly significant: it confirmed that gastric emptying is impaired enough on these drugs to change the standard surgical protocol.

Pancreatitis, Thyroid, and Gallbladder

Three organ-level risks with different evidence bases, different levels of certainty, and all three in the prescribing information.

Pancreatitis

GLP-1 receptors are expressed in pancreatic tissue, and there were early signals that GLP-1 drugs might trigger pancreatitis — inflammation of the pancreas, ranging from painful-and-recoverable to life-threatening. The drugs carry a warning in their prescribing information. The actual incidence in clinical trials is low: acute pancreatitis occurred in approximately 0.3% of semaglutide users during the STEP trials. Real-world pooled analyses through 2025 put the rate at 0.1 to 0.2 cases per 100 patient-years.

Whether the drug causes the pancreatitis or whether it is simply the underlying metabolic profile of obese patients (who have elevated baseline pancreatitis risk, especially those with hypertriglyceridemia) is genuinely debated. The low absolute rate does not mean zero risk. Contraindication: anyone with a personal history of acute or chronic pancreatitis should not take these drugs.

Thyroid C-Cell Tumors — the Boxed Warning

Every semaglutide and tirzepatide package carries a Boxed Warning — the FDA’s highest-level alert — for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). In rodent studies, GLP-1 receptor activation caused dose-dependent C-cell tumors. Rodent C-cells are more densely populated with GLP-1 receptors than human C-cells, which is the biological basis for the argument that the rodent signal may not translate. Large-scale human pharmacovigilance database reviews through 2025 have not found a statistically significant increase in thyroid cancer or MTC in human users.

Here is the problem with “no human signal yet”: medullary thyroid carcinoma typically takes 10–20 years to develop and present clinically. The oldest patients on high-dose semaglutide have been on it for fewer than five years. The boxed warning exists because rodent data established biological plausibility and because the consequences of missing an MTC signal in a drug taken by tens of millions of people are catastrophic. The human data will take another decade to be meaningful. Hard contraindication: any personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Non-negotiable.

Gallbladder Disease

This one is less speculative. Gallbladder-related adverse events — cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) — occur in approximately 2 to 4% of patients. The mechanism is dual: GLP-1 receptors in the gallbladder reduce its motility, causing bile to stagnate. Separately, rapid weight loss at any rate above about 1.5 kg per week alters bile composition and promotes cholesterol supersaturation, which is how gallstones form. GLP-1 drugs produce both conditions simultaneously. A July 2026 pooled analysis of the STEP trials confirmed a significant association between semaglutide 2.4 mg and gallbladder events. This is not a minor nuisance: gallbladder disease means pain, potential surgical removal, and hospital stays.

The Blindness Signal

A rare, potentially irreversible loss of vision that emerged from the real-world safety database and has now been classified as a recognized side effect in multiple jurisdictions.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a condition in which blood flow to the optic nerve is acutely reduced, causing sudden, painless vision loss. It is irreversible in most cases. There is no treatment. You wake up with significantly less vision in one eye and it does not come back.

A safety signal linking semaglutide to NAION emerged in mid-2024 from the FAERS database and retrospective cohort studies. A systematic review and meta-analysis published in the Asia-Pacific Journal of Ophthalmology in January 2026, evaluating ten studies, found that semaglutide use was associated with a pooled hazard ratio of 2.62 (95% CI: 1.81–3.80) for developing NAION compared to non-GLP-1 control medications. In practical terms: the absolute risk remains low (the condition itself is rare), but users of semaglutide appear to face more than 2.5 times the baseline risk of this particular vision loss.

In mid-2025, the European Medicines Agency (EMA) and Australian regulators officially classified NAION as a very rare side effect of semaglutide — a formal regulatory acknowledgment that the signal is real. Ophthalmic societies began recommending baseline optic nerve evaluations for high-risk patients (those with prior NAION, prior optic disc at risk anatomy, severe sleep apnea, hypertension) before starting GLP-1 therapy. This recommendation was not in the package insert. Your prescribing doctor may not have mentioned it. Your ophthalmologist may not know you are on the drug.

What Happens When You Stop

The STEP-1 extension trial published the number and it should have been front-page news. It was not.

The STEP-1 trial ran for 68 weeks. At the end, patients had lost a mean of nearly 15% of their body weight. Then a subset of participants stopped the drug and were followed for another 52 weeks. At the end of that year off semaglutide, they had regained two-thirds (67%) of their lost weight. Their cardiometabolic markers — blood pressure, HbA1c, lipids — worsened in parallel, returning toward pre-treatment baselines.

A January 2026 systematic review and meta-analysis published in The BMJ synthesized the evidence across multiple drugs and found that patients stopping newer weight-management medications regain weight at an average rate of 0.8 kg per month. On average, they return to their pre-treatment baseline weight within 18 months of stopping. The Cambridge University study from March 2026 found that even patients who eventually plateau keep only about 25% of their total weight loss long-term after stopping the drug.

This is not a drug failure. This is the biology of obesity working exactly as researchers expected. The hypothalamic circuits that drive appetite are not “cured” by GLP-1 therapy — they are suppressed while the drug is present. Remove the suppression and they reassert themselves. Obesity medicine researchers have said for decades that obesity is a chronic disease requiring chronic treatment, exactly as hypertension requires antihypertensives and depression requires antidepressants. The problem is not the science. The problem is what happens when the drug costs $1,300 a month and your insurance stops covering it.

“We would never tell a hypertensive patient to stop their medication because their blood pressure is controlled. But somehow patients and payers expect that obesity should be different — that you take the drug, lose the weight, and then you’re done. The biology says otherwise.” — Dr. Ania Jastreboff, Yale School of Medicine, on post-discontinuation rebound

The muscle mass question compounds the rebound problem in a way that is not discussed enough. When the weight comes back, it does not come back as muscle. It comes back as fat. The lean mass lost during therapy is not restored during regain. A patient who goes on and off GLP-1 therapy repeatedly may end up, over five or ten years, heavier in terms of fat percentage than they started — even if the scale shows the same number. This is called body composition drift, and the long-term data on it simply does not exist yet.

Who Should Never Take These

Hard contraindications based on evidence, not caution theater.

• Personal or family history of Medullary Thyroid Carcinoma (MTC) — Absolute contraindication. The thyroid C-cell tumor boxed warning is not advisory. If anyone in your immediate family has had MTC, these drugs are off the table.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — Same boxed warning, same absolute contraindication.
• Personal history of acute or chronic pancreatitis — The pancreatic tissue inflammation risk in someone with an already-damaged pancreas is not a risk worth taking.
• Severe gastroparesis or known motility disorders — Adding a drug that slows gastric emptying to a stomach that already doesn’t empty is asking for obstruction and hospitalization.
• Prior NAION or high-risk optic disc anatomy — Given the 2.6x hazard ratio for NAION, anyone who has already had an episode of ischemic optic neuropathy in one eye is at significantly elevated risk of losing vision in the other.
• Pregnancy or breastfeeding — No safety data. These drugs are not approved for use during pregnancy.
• Type 1 diabetes without appropriate clinical supervision — GLP-1 drugs are not insulin. They do not replace it. The interaction with existing insulin regimens requires careful management.
• Severe kidney disease (eGFR < 15) — Most GLP-1 drugs have limited or no data in end-stage renal disease and some are not approved in this population.
• Older adults with existing sarcopenia who are not committed to resistance training — Not a boxed warning, not a contraindication in the prescribing information. But the July 2025 elderly cohort data was stark enough that this belongs on any honest list. Losing muscle mass in a 70-year-old who is already at risk of falls is a potential path to permanent disability. This conversation has to happen before the prescription is written, not after.

The Forever Drug Business Model

A drug that stops working when you stop taking it, priced at $1,300 a month, in a country where 42% of adults are obese. The arithmetic is not accidental.

Novo Nordisk became, briefly, the most valuable company in Europe in 2023 on the back of semaglutide. Eli Lilly’s market capitalization surpassed that of every major oil company on tirzepatide revenues. The logic is straightforward: GLP-1 drugs address a chronic condition that requires chronic treatment. Obesity does not resolve on its own. The drug suppresses the disease mechanism while it is present. Stop the drug and the disease returns. If you are an investor, this is a perfect product. If you are a patient, the implication is that you are looking at a lifetime medication that, at list price, costs roughly $15,000 per year.

The insurance landscape is unraveling in real time. Many large employers and Medicare Part D (post-Inflation Reduction Act) began covering GLP-1 drugs for weight management in 2024–2025. By 2026, several major insurers began pulling back: the cost per enrolled member was unsustainable at current pricing without clear long-term cost offsets. The pharmaceutical companies argue that reducing cardiovascular events, hospitalizations, and kidney disease will produce net healthcare savings over a decade. That argument may ultimately be correct. But it requires the patient to stay on the drug for a decade — and 70% of patients are already off it by year two.

Compounded semaglutide — produced by specialty pharmacies using raw pharmaceutical-grade peptide — emerged as a lower-cost alternative during the official shortage period and flourished afterward. The FDA began aggressive enforcement actions against compounders in 2025 once it declared the Wegovy shortage resolved, though the legal battles over compounding rights continued into 2026. Compounded products are not FDA-approved; quality control is variable; dosing errors have been documented. The demand for compounded GLP-1 is, at its core, a market signal about what happens when a transformative drug is priced beyond the reach of the patients who need it most.

Novo Nordisk’s 2023 revenue from Ozempic and Wegovy alone exceeded the entire annual GDP of Bolivia. The company that discovered the drug — Novo Nordisk’s Danish laboratory, funded in part by decades of public research grants — holds global patents that expire between 2031 and 2036. Generic semaglutide is coming. The question is how many patients run out of options before it arrives.

What We Don’t Know Yet

The honest inventory of what the clinical trial database cannot tell you because the patients have not been on these drugs long enough.

Twenty-year organ effects

The oldest cohorts on high-dose semaglutide for weight management have been on it since Wegovy’s approval in 2021 — fewer than five years. GLP-1 receptors are expressed throughout the body: in the heart, the kidneys, the pancreas, the thyroid, the brain, the gut wall, and the lung. The drugs’ effects on some of these tissues over decades are genuinely unknown. The cardiovascular and renal benefits are documented at 3–5 years. What happens at 15 or 20 is extrapolation.

The thyroid signal we haven’t seen yet (or have we?)

Medullary thyroid carcinoma has a latency of 10–20 years. The boxed warning exists because the rodent data established biological plausibility for a mechanism that cannot be disproven in the human timeline yet. The 2025 epidemiological reviews that found “no signal” in humans looked at patients who had been on the drugs for at most 5–6 years. The signal, if it exists, may simply not have had time to appear. This is not catastrophizing — it is the correct reading of the available evidence window.

Long-term central nervous system effects

GLP-1 receptors are present in the brain, including regions involved in reward, memory, and mood. The drugs’ central effects — the suppression of “food noise,” the reported reduction in addictive cravings for alcohol and other substances in some patients — are not fully mechanistically understood. Clinical trials are now underway for GLP-1 drugs in Alzheimer’s disease, Parkinson’s disease, and addiction. These are potentially extraordinary findings. They also underscore that a drug class whose primary market is weight loss is doing something significant to the brain that we do not fully understand.

Triple agonists and the escalation problem

Eli Lilly’s retatrutide — a triple agonist hitting GLP-1, GIP, and glucagon receptors — achieved a mean weight loss of 28.7% in the TRIUMPH-4 trial in December 2025. Nearly 30% of body weight. In an individual who weighs 280 pounds, that is roughly 80 pounds. The lean mass loss at that degree of weight reduction, absent aggressive resistance training and protein supplementation, could be clinically significant in a way that 15% weight loss is not. The muscle problem does not scale linearly with weight loss percentage. Bigger losses mean more muscle at risk. The triple agonist era is arriving before the muscle-preservation protocol for the dual-agonist era has been established.